WO2002002597A3 - Peptide extended glycosylated polypeptides - Google Patents

Peptide extended glycosylated polypeptides Download PDF

Info

Publication number
WO2002002597A3
WO2002002597A3 PCT/DK2001/000459 DK0100459W WO0202597A3 WO 2002002597 A3 WO2002002597 A3 WO 2002002597A3 DK 0100459 W DK0100459 W DK 0100459W WO 0202597 A3 WO0202597 A3 WO 0202597A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycosylated polypeptides
polypeptide
interest
peptide extended
peptide
Prior art date
Application number
PCT/DK2001/000459
Other languages
French (fr)
Other versions
WO2002002597A2 (en
Inventor
Jens Sigurd Okkels
Anne Dam Jensen
Den Hazel Bart Van
Original Assignee
Maxygen Aps
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2000/000743 external-priority patent/WO2001049830A2/en
Priority claimed from PCT/DK2001/000090 external-priority patent/WO2001058493A1/en
Application filed by Maxygen Aps, Maxygen Holdings Ltd filed Critical Maxygen Aps
Priority to EP01944987A priority Critical patent/EP1299535A2/en
Priority to JP2002507849A priority patent/JP2004504016A/en
Priority to AU2001267337A priority patent/AU2001267337A1/en
Priority to CA002412882A priority patent/CA2412882A1/en
Publication of WO2002002597A2 publication Critical patent/WO2002002597A2/en
Publication of WO2002002597A3 publication Critical patent/WO2002002597A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01015—Polygalacturonase (3.2.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
    • C12Y602/01—Acid-Thiol Ligases (6.2.1)
    • C12Y602/01003—Long-chain-fatty-acid-CoA ligase (6.2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Glycosylated polypeptides comprising the primary structure NH2-X-Pp-COOH wherein X is a peptide addition comprising or contributing to a glycosylation site, and Pp is a polypeptide of interest or comprising the primary structure NH2-Px-X-Py-COOH, wherein Px is an N-terminal part of a polypeptide Pp of interest, Py is a C-terminal part of said polypeptide Pp, and X is a peptide addition comprising or contributing to a glycosylation site. The glycosylated polypeptides having improved properties as compared to the polypeptide of interest.
PCT/DK2001/000459 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides WO2002002597A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01944987A EP1299535A2 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides
JP2002507849A JP2004504016A (en) 2000-06-30 2001-06-29 Peptide-extended glycosylated polypeptides
AU2001267337A AU2001267337A1 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides
CA002412882A CA2412882A1 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200001027 2000-06-30
DKPA200001027 2000-06-30
DKPA200001092 2000-07-14
DKPA200001092 2000-07-14
PCT/DK2000/000743 WO2001049830A2 (en) 1999-12-30 2000-12-29 Improved lysosomal enzymes and lysosomal enzyme activators
DKPCT/DK00/00743 2000-12-29
PCT/DK2001/000090 WO2001058493A1 (en) 2000-02-11 2001-02-09 Conjugates of follicle stimulating hormones
DKPCT/DK01/00090 2001-02-09

Publications (2)

Publication Number Publication Date
WO2002002597A2 WO2002002597A2 (en) 2002-01-10
WO2002002597A3 true WO2002002597A3 (en) 2002-06-27

Family

ID=56290160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000459 WO2002002597A2 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides

Country Status (5)

Country Link
EP (1) EP1299535A2 (en)
JP (1) JP2004504016A (en)
AU (1) AU2001267337A1 (en)
CA (1) CA2412882A1 (en)
WO (1) WO2002002597A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023173B (en) * 2004-03-25 2012-08-08 埃欧金生物制品公司 Modified xylanases exhibiting improved expression

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
EP2292271A3 (en) 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
TR201900260T4 (en) 2002-06-17 2019-02-21 Chr Hansen As Improved method for producing an aspartic protease in a recombinant host organism.
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
CA2519092C (en) 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
PL1615945T3 (en) 2003-04-09 2012-03-30 Ratiopharm Gmbh Glycopegylation methods and proteins/peptides produced by the methods
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
BRPI0410164A (en) 2003-05-09 2006-05-16 Neose Technologies Inc compositions and methods for preparing human growth hormone glycosylation mutants
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
KR20060120141A (en) 2003-11-24 2006-11-24 네오스 테크놀로지스, 인크. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
KR101439880B1 (en) 2004-01-08 2014-09-12 라티오팜 게엠베하 O-linked glycosylation of peptides
ATE455861T1 (en) 2004-05-04 2010-02-15 Novo Nordisk Healthcare Ag O-LINKED GLYCOFORMS OF FACTOR VII AND METHOD FOR THE PRODUCTION THEREOF
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
JP5735194B2 (en) * 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド Biologically active protein with improved in vivo half-life
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (en) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス Glycopegylated factor IX
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
ES2516694T3 (en) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glycosylation of peptides through glycosylation sequences with O-binding
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
PE20081250A1 (en) * 2006-11-28 2008-10-07 Centelion Fc FUSIONS WITH RECEIVER FOR MODIFIED SOLUBLE FGF, WITH IMPROVED BIOLOGICAL ACTIVITY
BRPI0809670A8 (en) 2007-04-03 2018-12-18 Biogenerix Ag methods to increase stem cell production, to increase the number of granulocytes in an individual, to prevent, treat and alleviate myelosuppression that results from cancer therapy, to treat a condition in an individual, to treat neutropenia and thrombocytopenia in a mammal, to expand hematopoietic stem cells in culture, to increase hematopoiesis in an individual, to increase the number of hematopoietic progenitor cells in an individual, and to provide stable bone marrow graft, and, oral dosage form.
CN101778859B (en) 2007-06-12 2014-03-26 诺和诺德公司 Improved process for the production of nucleotide sugars
CN101970678B (en) 2007-06-21 2014-08-20 慕尼黑科技大学 Biological active proteins having increased in vivo and/or vitro stability
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
JP5769142B2 (en) * 2007-09-04 2015-08-26 独立行政法人酒類総合研究所 Method for high secretion of heterologous proteins in Pichia yeast
CN103497246B (en) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 The Factor VlII molecule puted together
JP2010183885A (en) * 2009-02-13 2010-08-26 Kobe Univ Method for producing protein and expression vector used therefor
CN102883734B (en) 2010-05-21 2018-01-02 Xl-蛋白有限责任公司 The proline of biosynthesis/alanine random coil polypeptide and application thereof
EP2638152B1 (en) * 2010-11-08 2016-08-31 Amicus Therapeutics, Inc. Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
US20160296632A1 (en) * 2013-11-13 2016-10-13 Aequus Biopharma, Inc. Engineered glycoproteins and uses thereof
WO2015091130A1 (en) * 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Method for improving the recombinant production of soluble fusion polypeptides
CA2929149A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Improved recombinant polypeptide production methods
HRP20220304T1 (en) 2015-06-24 2022-05-13 F. Hoffmann - La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
PE20181004A1 (en) 2015-10-02 2018-06-26 Hoffmann La Roche BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE
JP2020508289A (en) * 2017-01-31 2020-03-19 レジェンクスバイオ インコーポレーテッド Treatment of mucopolysaccharidosis type I with fully human glycosylated human α-L-iduronidase (IDUA)
AU2018298133A1 (en) 2017-07-06 2020-01-23 The Trustees Of The University Of Pennsylvania AAV9-mediated gene therapy for treating mucopolysaccharidosis type I
US11819539B2 (en) 2017-09-22 2023-11-21 The Trustees Of The University Of Pennsylvania Gene therapy for treating Mucopolysaccharidosis type II

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370205A2 (en) * 1988-09-29 1990-05-30 Kyowa Hakko Kogyo Co., Ltd. Glycosylated polypeptides
WO1990007573A1 (en) * 1988-12-23 1990-07-12 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
WO1999013081A1 (en) * 1997-09-08 1999-03-18 Akzo Nobel N.V. EXPRESSION OF GONADOTROPINS IN $i(DICTYOSTELIUM)
WO1999054342A1 (en) * 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370205A2 (en) * 1988-09-29 1990-05-30 Kyowa Hakko Kogyo Co., Ltd. Glycosylated polypeptides
WO1990007573A1 (en) * 1988-12-23 1990-07-12 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
WO1999013081A1 (en) * 1997-09-08 1999-03-18 Akzo Nobel N.V. EXPRESSION OF GONADOTROPINS IN $i(DICTYOSTELIUM)
WO1999054342A1 (en) * 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANTOR ALAN B ET AL: "Phosphorylation of Asn-linked oligosaccharides located at novel sites on the lysosomal enzyme cathepsin D.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 32, 1992, pages 23357 - 23363, XP002173975, ISSN: 0021-9258 *
DOEBBER T W ET AL: "ENHANCED MACROPHAGE UPTAKE OF SYNTHETICALLY GLYCOSYLATED HUMAN PLACENTAL BETA GLUCO CEREBROSIDASE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 257, no. 5, 1982, pages 2193 - 2199, XP001002183, ISSN: 0021-9258 *
FULLER MARIA ET AL: "Receptor mediated binding of two glycosylation forms of N-acetylgalactosamine-4-sulphatase.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1406, no. 3, 28 April 1998 (1998-04-28), pages 283 - 290, XP001002494, ISSN: 0006-3002 *
FURBISH F S ET AL: "UPTAKE AND DISTRIBUTION OF PLACENTAL GLUCO CEREBROSIDASE IN RAT HEPATIC CELLS AND EFFECTS OF SEQUENTIAL DEGLYCOSYLATION", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 673, no. 4, 1981, pages 425 - 434, XP001002396, ISSN: 0006-3002 *
MURRAY G J ET AL: "TARGETING OF SYNTHETICALLY GLYCOSYLATED HUMAN PLACENTAL GLUCOCEREBROSIDASE", BIOCHEMICAL MEDICINE, vol. 34, no. 2, 1985, pages 241 - 246, XP001042190, ISSN: 0006-2944 *
WARREN CHARLES E: "Glycosylation.", CURRENT OPINION IN BIOTECHNOLOGY, vol. 4, no. 5, 1993, pages 596 - 602, XP001042143, ISSN: 0958-1669 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023173B (en) * 2004-03-25 2012-08-08 埃欧金生物制品公司 Modified xylanases exhibiting improved expression

Also Published As

Publication number Publication date
CA2412882A1 (en) 2002-01-10
AU2001267337A1 (en) 2002-01-14
WO2002002597A2 (en) 2002-01-10
EP1299535A2 (en) 2003-04-09
JP2004504016A (en) 2004-02-12

Similar Documents

Publication Publication Date Title
WO2002002597A3 (en) Peptide extended glycosylated polypeptides
HK1119955A1 (en) Modified kunitz domain polypeptide
WO2001000666A3 (en) Self-aligning peptides derived from human elastin and other fibrous proteins
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
EP2253645A3 (en) Factor VIII Polypeptide
CA2155185A1 (en) Totally synthetic affinity reagents
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
BR9407377A (en) Hybrid toxin
WO2002002621A3 (en) Mammalian secreted proteins
WO1999003881A3 (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
WO1998005685A3 (en) Self-aligning peptides derived from elastin and other fibrous proteins
IL153943A0 (en) SUBSTRATES AND ASSAYS FOR beta-SECRETASE ACTIVITY
WO2004043403A3 (en) Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
WO2004094592A3 (en) Polymer-conjugated glycosylated neublastin
WO2000058465A3 (en) Flint polypeptide analogs
CA2077590A1 (en) Recombinant dna coding for a protein with endochitinase activity
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
AU8727001A (en) A novel polypeptide-tumor suppressor protein 63 and the polynucleotide encoding said polypeptide
AU9538501A (en) A novel polypeptide-mouse transient receptor potential protein 2 (trp2)12 and the polynucleotide encoding said polypeptide
WO2002059317A3 (en) Cub domain protein zcub3 and materials and methods for making it
AU2001233567A1 (en) A novel polypeptide, human protein 9 of short-chain scorpion toxin and the polynucleotide encoding the polypeptide
AU8953301A (en) A novel polypeptide, a zinc-finger protein 34 and the polynucleotide encoding the polypeptide
WO2001053344A3 (en) Chondromodulin-i related peptide
FR2787454B1 (en) TOPOISOMERASE II INHIBITOR

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001944987

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001267337

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2412882

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 54/CHENP/2003

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2001944987

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001944987

Country of ref document: EP